Biosimilar Uptake Is More Related to Practice Setting Than Patient, Physician Characteristics

Practice setting and hospital outpatient ownership status had the strongest associations with the adoption of the first three biosimilars launched in Medicare, according to a recent study published in JAMA Network Open. By analyzing use of the biosimilar versions of filgrastim and infliximab among more than 40,000 Medicare fee-for service beneficiaries, the study found that patient and physician characteristics did not strongly correlate with whether a patient received a biosimilar. While the setting of administration had the greatest association with biosimilar uptake, the direction of association differed by drug class. For instance, a patient in a hospital outpatient setting was 16 percentage points less likely to receive a filgrastim biosimilar than a patient in an office setting, but 3 percentage points more likely to receive an infliximab biosimilar.

© 2021 MMIT

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today